Church & Dwight Co., Inc. (NYSE: CHD) today announced the Company exceeded its outlook with stronger than expected sales growth. Full year 2024 net sales increased 4.1% to $6,107.1 million, ahead of ...
Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback